Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth G Kowalski

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
British Journal of Clinical Pharmacology|June 26, 2014
Covariate selection in pharmacometric analyses: a review of methodsMatthew M Hutmacher, Kenneth G Kowalski
Journal of Pharmacokinetics and Pharmacodynamics|December 7, 2007
Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patientsMatthew M Hutmacher, Sriram Krishnaswami, Kenneth G Kowalski
Journal of Pharmacokinetics and Pharmacodynamics|December 2, 2005
Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonistMatthew M Hutmacher, Debu Mukherjee, Kenneth G Kowalski, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 24, 2004
A two-part mixture model for longitudinal adverse event severity dataKenneth G Kowalski, Lynn McFadyen, Matthew M Hutmacher, et al.
Epilepsia|October 15, 2014
Vigabatrin pediatric dosing information for refractory complex partial seizures: results from a population dose-response analysisJace C Nielsen, Dwain Tolbert, Mahlaqa Patel, et al.
Clinical Pharmacokinetics|August 31, 2014
Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasmsJace C Nielsen, Kenneth G Kowalski, Aziz Karim, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 4, 2023
Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trialsKumar Kandadi Muralidharan, Kenneth G Kowalski, Xiao Tong, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 4, 2023
Correction to: Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trialsKumar Kandadi Muralidharan, Kenneth G Kowalski, Xiao Tong, et al.
Clinical Ophthalmology (Auckland, N.Z.)|March 4, 2015
Population pharmacokinetics of pegaptanib sodium (Macugen(®)) in patients with diabetic macular edemaAnthony S Basile, Matthew M Hutmacher, Kenneth G Kowalski, et al.
Journal of Clinical Pharmacology|August 14, 2014
Population dose-response analysis of daily seizure count following vigabatrin therapy in adult and pediatric patients with refractory complex partial seizuresJace C Nielsen, Matthew M Hutmacher, David L Wesche, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
British Journal of Clinical Pharmacology|June 26, 2014
Covariate selection in pharmacometric analyses: a review of methodsMatthew M Hutmacher, Kenneth G Kowalski
Journal of Pharmacokinetics and Pharmacodynamics|December 7, 2007
Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patientsMatthew M Hutmacher, Sriram Krishnaswami, Kenneth G Kowalski
Journal of Pharmacokinetics and Pharmacodynamics|December 2, 2005
Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonistMatthew M Hutmacher, Debu Mukherjee, Kenneth G Kowalski, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 24, 2004
A two-part mixture model for longitudinal adverse event severity dataKenneth G Kowalski, Lynn McFadyen, Matthew M Hutmacher, et al.
Epilepsia|October 15, 2014
Vigabatrin pediatric dosing information for refractory complex partial seizures: results from a population dose-response analysisJace C Nielsen, Dwain Tolbert, Mahlaqa Patel, et al.
Clinical Pharmacokinetics|August 31, 2014
Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasmsJace C Nielsen, Kenneth G Kowalski, Aziz Karim, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 4, 2023
Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trialsKumar Kandadi Muralidharan, Kenneth G Kowalski, Xiao Tong, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 4, 2023
Correction to: Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trialsKumar Kandadi Muralidharan, Kenneth G Kowalski, Xiao Tong, et al.
Clinical Ophthalmology (Auckland, N.Z.)|March 4, 2015
Population pharmacokinetics of pegaptanib sodium (Macugen(®)) in patients with diabetic macular edemaAnthony S Basile, Matthew M Hutmacher, Kenneth G Kowalski, et al.
Journal of Clinical Pharmacology|August 14, 2014
Population dose-response analysis of daily seizure count following vigabatrin therapy in adult and pediatric patients with refractory complex partial seizuresJace C Nielsen, Matthew M Hutmacher, David L Wesche, et al.
Pageof 2